NCT00485186

Brief Summary

The extend of steroid biosynthesis and action is mainly dependent on underlying genetic polymorphisms and gene mutations. These sequence variations in multiple genes involved in steroid biosynthesis and action cause different diseases (for example congenital adrenal hyperplasia or disorders of sex development). In addition, sequence variations in several other genes may influence the severity of a genetically caused disease of steroid biosynthesis or action. By this, the differences in an observed phenotype may be explained. Within the study all genes necessary for adrenal and gonadal steroid biosynthesis and several genes which are known to influence the action of steroid hormones will be analysed in patients with congenital disorders of adrenal and gonadal steroid biosynthesis, disorders of steroid action and disorders of sex development. The primary aim is to set up a correlation of the disease phenotype with the different genotypes detected.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2007

Longer than P75 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

June 8, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 12, 2007

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

September 5, 2013

Status Verified

September 1, 2013

Enrollment Period

6 years

First QC Date

June 8, 2007

Last Update Submit

September 4, 2013

Conditions

Study Arms (2)

1

2

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Inclusion Criteria: * Disorders of Sex Development * Congenital Adrenal Hyperplasia * Congenital Adrenal Hypoplasia * Adrenal Insufficiency * Mineralocorticoid Deficiency * Salt-loss

You may qualify if:

  • Disorders of Sex Development
  • Congenital Adrenal Hyperplasia
  • Congenital Adrenal Hypoplasia
  • Adrenal Insufficiency
  • Mineralocorticoid Deficiency
  • Salt-loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Disorders of Sex DevelopmentAdrenal Hyperplasia, CongenitalHypoadrenocorticism, FamilialAdrenal InsufficiencyOvotesticular Disorders of Sex Development

Condition Hierarchy (Ancestors)

Urogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGonadal DisordersEndocrine System DiseasesAdrenogenital SyndromeGenetic Diseases, InbornSteroid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsMetabolic DiseasesNutritional and Metabolic DiseasesAdrenal Gland DiseasesAddison Disease

Study Officials

  • Paul-Martin Holterhus, MD

    University Hospital Schleswig-Holstein

    STUDY CHAIR
  • Felix G Riepe, MD

    University Hospital Schleswig-Holstein

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

June 8, 2007

First Posted

June 12, 2007

Study Start

June 1, 2007

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

September 5, 2013

Record last verified: 2013-09